Drug Discovery Services Market Research Report – Forecast to 2023

Description:

Drug Discovery Services Market Research Report: By Drug Type (Small Molecule Drug, Biologics), by Type (DMPK, Pharmaceutical Services, Others), by Therapeutic Area (Oncology, Others), by Process, by Technology, and by End-User – Global Forecast Till 2023

Market Scenario

Drug discovery is the process of designing a new drug. The most common methods employed for drug discovery are molecular manipulation, random screening, drug metabolites, molecular designing, and serendipity. Drug discovery services are specifically designed to minimize the costs and timelines of drug discovery.

It is noted that the increasing demand for cancer treatment, technological advancements, and increasing healthcare expenditure are the key factors driving the drug discovery services market. According to the World Health Organization (WHO), cancer is one of the leading causes of mortality worldwide. The disease was responsible for 8.8 million deaths in 2015. The most common cancers are lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer. Cancer-causing infections are responsible for up to 25% cases of cancer in the low- and middle-income countries.

Various other factors such as the growing awareness about chronic diseases, increasing patient pool, unmet medical needs, patent expiration of blockbuster drugs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global drug discovery services market.

Despite these drivers, there are some setbacks associated with the drug discovery services market. The huge capital investment with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries may hinder the growth of the drug discovery services market to a considerable extent.

It is estimated that the drug discovery services market is expected to grow at a CAGR of 10.8% during the forecast period of 2017–2023.

Intended Audience

- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institutes
- Academic Institutes and Universities

Segmentation

The global drug discovery services market is segmented by drug type, types of services, technology, therapeutic area, process, and end-user.

On the basis of drug type, the drug discovery services market is classified as small molecule drug and biologics drug.

On the basis of types of services, the drug discovery services market is classified as Drug
Metabolism and Pharmacokinetics (DMPK) services, pharmaceutical services, medicinal chemistry, and biological services.

On the basis of technology, the drug discovery services market is classified as high throughput screening, biochips, pharmacogenomics and pharmacogenetics, combinatorial chemistry, nanotechnology, spectroscopy, metabolomics, and others.

On the basis of therapeutic area, the drug discovery services market is classified as oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and others.

On the basis of process, the drug discovery services market is classified as target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation.

On the basis of end-user, the drug discovery services market is segmented into hospitals and clinics, pharmaceutical companies, biotechnology companies, research institutes, and others.

**Research Methodology**

Sources: Annual reports, Press release, White paper, and Company presentation

**Regional Analysis**

The Americas dominates the drug discovery services market owing to the increasing prevalence of chronic diseases and high healthcare expenditure. According to the data suggested by the Center for Disease Control and Prevention (CDC), around 92.1 million adults have at least one type of cardiovascular disease. It is also reported that around 15.1% of adults in the United States i.e. 36.5 million adults smoked cigarettes in 2015, which accounted for more than 480,000 deaths each year. Nearly 86% of the healthcare cost in the United States i.e. USD 2.7 trillion is spent for people with chronic and mental health conditions.

Europe holds the second position in the drug discovery services market. The financial support by the government towards research and development and patent expiration of various blockbuster drugs are expected to drive the European drug discovery services market. Various biologic drugs such as Genentech's Rituxan, Abbott & Eisai's Humira, and J&J's Remicade are likely to lose their patent protection in the coming years.

Asia Pacific is the fastest growing drug discovery services market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was
nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.

The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.

**Key Players**

Chapter 7. Global Drug Discovery Services Market, by Types of Services

7.1 Introduction

7.2 Drug Metabolism and Pharmacokinetics (DMPK) Services

7.2.1 Market Estimates & Forecast, 2017–2023

7.3 Pharmaceutical Services

7.3.1 Market Estimates & Forecast, 2017–2023

7.4 Medicinal Chemistry

7.4.1 Market Estimates & Forecast, 2017–2023

7.5 Biological Services

7.5.1 Market Estimates & Forecast, 2017–2023

7.6 Medication

7.6.1 Market Estimates & Forecast, 2017–2023

Chapter 8. Global Drug Discovery Services Market, by Technology

8.1 Introduction

8.2 High Throughput Screening

8.2.1 Market Estimates & Forecast, 2017–2023

8.3 Biochips

8.3.1 Market Estimates & Forecast, 2017–2023

8.4 Pharmacogenomics and Pharmacogenetics

8.4.1 Market Estimates & Forecast, 2017–2023

8.5 Combinatorial Chemistry

8.5.1 Market Estimates & Forecast, 2017–2023

8.6 Nanotechnology

8.6.1 Market Estimates & Forecast, 2017–2023

8.7 Spectroscopy

8.7.1 Market Estimates & Forecast, 2017–2023

8.8 Metabolomics


8.9 Others

8.9.1 Market Estimates & Forecast, 2017–2023

Chapter 9. Global Drug Discovery Services Market, by Therapeutic Area

9.1 Introduction

9.2 Oncology

9.2.1 Market Estimates & Forecast, 2017–2023

9.3 Cardiovascular Diseases

9.3.1 Market Estimates & Forecast, 2017–2023

9.4 Respiratory Diseases

9.4.1 Market Estimates & Forecast, 2017–2023

9.5 Diabetes

9.5.1 Market Estimates & Forecast, 2017–2023

9.6 Others


Chapter 10. Global Drug Discovery Services Market, by Process

10.1 Introduction

10.2 Target Selection

10.2.1 Market Estimates & Forecast, 2017–2023

10.3 Target Validation
10.3.1 Market Estimates & Forecast, 2017–2023
10.4 Hit-To-Lead Identification
10.4.1 Market Estimates & Forecast, 2017–2023
10.5 Lead Optimization
10.5.1 Market Estimates & Forecast, 2017–2023
10.6 Candidate Validation
10.6.1 Market Estimates & Forecast, 2017–2023

Chapter 11. Global Drug Discovery Services Market, by End-User
11.1 Introduction
11.2 Hospitals
11.2.1 Market Estimates & Forecast, 2017–2023
11.3 Clinics
11.3.1 Market Estimates & Forecast, 2017–2023
11.4 Diagnostic Centers
11.4.1 Market Estimates & Forecast, 2017–2023
11.5 Drug Stores
11.5.1 Market Estimates & Forecast, 2017–2023
11.6 Pharmacies
11.6.1 Market Estimates & Forecast, 2017–2023
11.7 Others
11.7.1 Market Estimates & Forecast, 2017–2023

Chapter 12. Global Drug Discovery Services Market, by Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.1.1 U.S.
12.2.1.1 Canada
12.2.2 South America
12.3 Europe
12.3.1 Western Europe
12.3.1.1 Germany
12.3.1.2 France
12.3.1.3 Italy
12.3.1.4 Spain
12.3.1.5 U.K.
12.3.1.6 Rest of Western Europe
12.3.2 Eastern Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 Republic of Korea
12.4.6 Rest of Asia Pacific
12.5 The Middle East & Africa
12.5.1 United Arab Emirates
12.5.2 Saudi Arabia
12.5.3 Oman
Chapter 13 Company Landscape

13.1 Introduction
13.2 Market Share Analysis
13.3 Key Development & Strategies
13.3.1 Key Developments

Chapter 14 Company Profiles

14.1 Eli Lilly and Company's
14.1.1 Company Overview
14.1.2 Types Overview
14.1.3 Financials
14.1.4 SWOT Analysis

14.2 Thermo Fisher Scientific
14.2.1 Company Overview
14.2.2 Types Overview
14.2.3 Financial Overview
14.2.4 Key Developments
14.2.5 SWOT Analysis

14.3 GVK Biosciences
14.3.1 Company Overview
14.3.2 Types Overview
14.3.3 Financial Overview
14.3.4 Key Development
14.3.5 SWOT Analysis

14.4 Merck
14.4.1 Company Overview
14.4.2 Types/Business Segment Overview
14.4.3 Financial Overview
14.4.4 Key Development
14.4.5 SWOT Analysis

14.5 GLAXOSMITHKLINE
14.5.1 Company Overview
14.5.2 Types Overview
14.5.3 Financial overview
14.5.4 Key Developments

14.6 Albany Molecular Research Inc. (AMRI)
14.6.1 Company Overview
14.6.2 Types Overview
14.6.3 Financial Overview
14.6.4 Key Developments

14.7 CHARLES RIVER LABORATORIES INTERNATIONAL
14.7.1 Overview
14.7.2 Types Overview
14.7.3 Financials
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.8 Others

Chapter 15 MRFR Conclusion

15.1 Key Findings

15.1.1 From CEO’s View Point

15.1.2 Unmet Needs of the Market

15.2 Key Companies to Watch

15.3 Prediction of the Drug Discovery Services Industry

Chapter 16 Appendix

LIST OF TABLES

Table 1 Drug Discovery Services Industry Synopsis, 2017–2023

Table 2 Drug Discovery Services Market Estimates and Forecast, 2017–2023, (USD Million)

Table 3 Drug Discovery Services Market, by Region, 2017–2023, (USD Million)

Table 4 Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 5 Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 6 Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 7 Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)

Table 8 Drug Discovery Services Market, by Process, 2017–2023, (USD Million)

Table 9 Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)

Table 10 North America Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 11 North America Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 12 North America Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 13 North America Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)

Table 14 North America Drug Discovery Services Market, by Process, 2017–2023, (USD Million)

Table 15 North America Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)

Table 16 U.S. Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 17 U.S. Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 18 U.S. Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 19 U.S. Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)


Table 21 U.S. Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)

Table 22 Canada Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 23 Canada Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 24 Canada Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 25 Canada Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)

Table 26 Canada Drug Discovery Services Market, by Process, 2017–2023, (USD Million)

Table 27 Canada Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)

Table 28 South America Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 29 South America Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 30 South America Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 31 South America Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)

Table 32 South America Drug Discovery Services Market, by Process, 2017–2023, (USD Million)

Table 33 South America Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)

Table 34 Europe Drug Discovery Services Market, by Drug Type, 2017–2023, (USD Million)

Table 35 Europe Drug Discovery Services Market, by Types of Services, 2017–2023, (USD Million)

Table 36 Europe Drug Discovery Services Market, by Technology, 2017–2023, (USD Million)

Table 37 Europe Drug Discovery Services Market, by Therapeutic Area, 2017–2023, (USD Million)

Table 38 Europe Drug Discovery Services Market, by Process, 2017–2023, (USD Million)

Table 39 Europe Drug Discovery Services Market, by End-User, 2017–2023, (USD Million)
Figure 24 GVK Biosciences: Geographical Revenue
Figure 25 Merck: Key Financials
Figure 26 Merck: Segmental Revenue
Figure 27 Merck: Geographical Revenue
Figure 28 GLAXOSMITHKLINE: Key Financials
Figure 29 GLAXOSMITHKLINE: Segmental Revenue
Figure 30 GLAXOSMITHKLINE Geographical Revenue
Figure 31 Albany Molecular Research Inc. (AMRI): Key Financials
Figure 32 Albany Molecular Research Inc. (AMRI): Segmental Revenue
Figure 33 Albany Molecular Research Inc. (AMRI): Geographical Revenue
Figure 34 CHARLES RIVER LABORATORIES INTERNATIONAL: Key Financials
Figure 35 CHARLES RIVER LABORATORIES INTERNATIONAL: Segmental Revenue
Figure 36 CHARLES RIVER LABORATORIES INTERNATIONAL: Geographical Revenue